Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more
Nurix Therapeutics Inc (NRIX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of August 2025: -0.154x
Based on the latest financial reports, Nurix Therapeutics Inc (NRIX) has a cash flow conversion efficiency ratio of -0.154x as of August 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.38 Million) by net assets ($372.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nurix Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nurix Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nurix Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nurix Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S.ENER.ELEC.SP.GDR REGS 1
F:ECEA
|
N/A |
|
Fangda Special Steel Technology Co Ltd
SHG:600507
|
0.015x |
|
Israel Corporation Ltd
OTCGREY:IRLCF
|
0.038x |
|
Anhui Tongguan Copper Foil Group Co. Ltd.
SHE:301217
|
N/A |
|
Herman Miller Inc
F:MHR
|
0.047x |
|
Xinjiang Tianfu Energy Co Ltd
SHG:600509
|
0.047x |
|
Ichor Holdings Ltd
NASDAQ:ICHR
|
0.014x |
|
Shuangliang Eco-Energy Systems Co Ltd
SHG:600481
|
0.229x |
Annual Cash Flow Conversion Efficiency for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nurix Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | $526.99 Million | $-172.58 Million | -0.327x | +19.30% |
| 2023-11-30 | $200.49 Million | $-81.36 Million | -0.406x | +22.88% |
| 2022-11-30 | $303.70 Million | $-159.81 Million | -0.526x | -113.50% |
| 2021-11-30 | $342.30 Million | $-84.36 Million | -0.246x | -89325.95% |
| 2020-11-30 | $290.27 Million | $-80.00K | 0.000x | +99.56% |
| 2019-11-30 | $-9.52 Million | $601.00K | -0.063x | +97.74% |
| 2018-11-30 | $11.35 Million | $-31.68 Million | -2.791x | -- |